Sugi Predict

Sugi Predict / Compounds / SCHEMBL3519944

SCHEMBL3519944

SCHEMBL3519944

CC(C)CN(Cc1ccc2c(c1)OCCO2)C(=O)C1CN(Cc2nn(C)cc2Cl)CCO1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PROKR2 Q8NFJ6 4/20 0.56
▸ GRN P28799 1/20 0.38
▸ SORT1 Q99523 1/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ GRM2 Q14416 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ HTT P42858 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ UBE2M P61081 1/20 0.33
▸ DCUN1D1 Q96GG9 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ CHRM5 P08912 1/20 0.33
▸ NR1I2 O75469 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ MCHR1 Q99705 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3517248 0.87 PROKR2 (0.64) PROKR2GRNSORT1KMT2AKDM4E
SCHEMBL3520969 0.86 PROKR2 (0.54) PROKR2GRNSORT1KMT2AKDM4E
SCHEMBL3518893 0.86 PROKR2 (0.52) PROKR2GRNSORT1KMT2AKDM4E
SCHEMBL3518042 0.86 PROKR2 (0.52) PROKR2GRNSORT1KMT2AKDM4E
SCHEMBL3516648 0.85 PROKR2 (0.55) PROKR2GRNSORT1KMT2AKDM4E
SCHEMBL3518041 0.85 PROKR2 (0.59) PROKR2GRNSORT1KMT2AKDM4E
SCHEMBL3518033 0.85 PROKR2 (0.59) PROKR2GRNSORT1KMT2AKDM4E
SCHEMBL3520200 0.85 PROKR2 (0.59) PROKR2GRNSORT1KMT2AKDM4E
SCHEMBL3520269 0.85 PROKR2 (0.61) PROKR2GRNSORT1KMT2AKDM4E
SCHEMBL3518764 0.84 PROKR2 (0.53) PROKR2GRNSORT1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 — — EP claimed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 — — US claimed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 — — US claimed
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 — — EP disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 — — US disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 — — US disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 — — US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 — — US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 — — US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists PROKR2, PROKR1, NTSR2 PROKR2 1/4885GRN 562/4885SORT1 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.